CHEC PR

chec-pr-logo

CHEC PR has developed orally available peptide compounds for cell degeneration due to inflammation, oxidative stress or protein aggregation. The goal of the organization is to extend a large volume of animal data, showing excellent efficacy in neurodegenerative models, to the modeled human diseases. Possible lead indications for which there are proof of concept data: Multiple Sclerosis, Alzheimerโ€™s and/or Parkinsonโ€™s Disease, Central Nervous System Injuries, and Seizure Disorders. There is v... ery limited industry progress for the above indications. The current treatments for MS relapse are by injection with no long term benefit for neurodegeneration and disability and highly variable safety profiles. No combined anti-inflammatory or aggregate disposal therapies are presently available for neurodegenerative disorders like Alzheimerโ€™s, Parkinsonโ€™s, or Huntingtonโ€™s diseases. CHECs are unique because they target all the principal cellular pathologies in degenerative diseases (inflammation, cell death, protein aggregation) in an orally available formulation. Company advisors are Timothy Cunningham, Ph.D., who discovered and isolated the compounds, and Jeffrey Greenstein, M.D., who is a neurologist/immunologist that will supervise clinical applications. The peptides are protected by issued US patents and several patent applications. CHEC PR takes a flexible position for selection of initial lead indication and for equity sharing. Accommodating investor interest and needs in this way is expected to expedite capitalization and clinical development, Key Milestones: - Selection of lead indication - IND enablement thru Phase I Summary: CHEC PR has a highly qualified team of advisors that have developed these novel peptide therapeutics with potential is in several multi-billion dollar markets. The peptide is orally available, CNS penetrant, with no demonstrated safety concerns .

#SimilarOrganizations #People #Website #More

CHEC PR

Social Links:

Industry:
Biotechnology Medical

Founded:
2015-07-01

Address:
Philadelphia, Pennsylvania, United States

Country:
United States

Website Url:
http://www.checkpagerank.net

Total Employee:
1+

Status:
Active

Total Funding:
0

Technology used in webpage:
Viewport Meta IPhone / Mobile Compatible SPF SSL By Default Google Font API Google Analytics LetsEncrypt Google Tag Manager Content Delivery Network Google Universal Analytics


Similar Organizations

tarsa-therapeutics-logo

Tarsa Therapeutics

Tarsa Therapeutics develops an oral formulation of calcitonin for the treatment and prevention of postmenopausal osteoporosis.

Current Employees Featured

timothy-j-cunningham_image

Timothy J Cunningham
Timothy J Cunningham Chief Scientific Advisor @ CHEC PR
Chief Scientific Advisor

jeffrey-i-greenstein_image

Jeffrey I Greenstein
Jeffrey I Greenstein Chief Medical Advisor @ CHEC PR
Chief Medical Advisor

Official Site Inspections

http://www.checkpagerank.net Semrush global rank: 75.91 K Semrush visits lastest month: 1.43 M

  • Host name: host.onlyonlinedevelopment.com
  • IP address: 96.30.9.108
  • Location: Lansing United States
  • Latitude: 42.7348
  • Longitude: -84.6245
  • Metro Code: 551
  • Timezone: America/Detroit
  • Postal: 48917

Loading ...

More informations about "CHEC PR" on Search Engine